Shares in Crucell NV surged more than 55 percent Friday on news that Johnson & Johnson, which already holds a 17.9 percent stake in the company, was lining up a €1.75 billion (US$2.3 billion) bid, valued at €24.75 per share, to acquire the Dutch vaccine maker outright. (BioWorld International)

Roche AG and reMYND will join forces to develop two classes of compounds against Parkinson's disease and Alzheimer's disease. The total deal is worth as much as $637 million to reMYND as milestones are met. (BioWorld International)